Blueprint Medicines Corporation (BPMC)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 108.34 |
| Open | 108.71 |
| Bid | 106.35 x 200 |
| Ask | 106.75 x 100 |
| Day's range | 106.01 - 109.02 |
| 52-week range | 43.89 - 110.93 |
| Volume | |
| Avg. volume | 823,756 |
| Market cap | 6.793B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.82 |
| Earnings date | 31 July 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 118.13 |
ZacksZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
PR NewswireBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective May 1, 2024, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 6,400 shares of its common stock and an aggregate of 3,200 restricted stock units (RSUs) to two new employees under Blueprint Medicines' 2020 Inducement Plan.
Zacks5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
© 2024 Yahoo. All rights reserved.